#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	3540	16S	1529	1529	100.0	16S.l15.c17.ctg.1	2262	456.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1596	1596	C	566	C	460	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	5648	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3841	439.0	0	.	n	.	0	T695C	SNP	695	695	T	1199	1199	C	453	C,A,T	340,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	5648	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3841	439.0	0	.	n	.	0	G1337A	SNP	1337	1337	G	1841	1841	A	501	A,C,G	405,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	5648	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3841	439.0	0	.	n	.	0	T1971C	SNP	1971	1971	T	2475	2475	C	509	C,T,A	407,2,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	5648	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3841	439.0	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3101	3101	T	450	T,C,G	280,77,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	5648	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3841	439.0	1	SNP	n	A2045G	0	.	.	2045	2045	A	2549	2549	A	564	A,C,G,T	447,1,1,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	526	folP	852	852	100.0	folP.l15.c4.ctg.1	1781	88.3	1	SNP	p	R228S	1	.	.	682	684	AGC	1142	1144	AGC	117;117;118	A;G;C,T	85;87;88,1	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1166	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3757	92.7	1	SNP	p	S91F	0	.	.	271	273	TCC	769	771	TCC	95;94;94	T;C;C	71;76;77	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1166	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3757	92.7	1	SNP	p	D95N	0	.	.	283	285	GAC	781	783	GAC	97;96;97	G;A,G;C	77;74,1;78	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1166	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3757	92.7	1	SNP	p	D95G	0	.	.	283	285	GAC	781	783	GAC	97;96;97	G;A,G;C	77;74,1;78	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_W_01449	mtrR.WHO_W_01449	1	1	27	506	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1762	86.0	1	SNP	p	G45D	1	.	.	133	135	GAC	621	623	GAC	159;158;159	G;A;C	125;115;123	mtrR.WHO_W_01449:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	256	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1376	55.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1188	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3288	107.5	1	SNP	p	D86N	0	.	.	256	258	GAC	816	818	GAC	145;143;143	G;A;C	112;103;114	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1188	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3288	107.5	1	SNP	p	S87I	0	.	.	259	261	AGT	819	821	AGT	143;145;144	A;G;T,A	109;111;109,1	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1188	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3288	107.5	1	SNP	p	S87R	0	.	.	259	261	AGT	819	821	AGT	143;145;144	A;G;T,A	109;111;109,1	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1188	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3288	107.5	1	SNP	p	S87W	0	.	.	259	261	AGT	819	821	AGT	143;145;144	A;G;T,A	109;111;109,1	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1188	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3288	107.5	1	SNP	p	S88P	0	.	.	262	264	TCC	822	824	TCC	144;143;142	T;C;C	105;111;110	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1012	parE	1986	1986	100.0	parE.l6.c17.ctg.1	2879	104.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1679	1681	GGC	137;137;135	G;G;C,T,G	109;104;102,1,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	818	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2680	90.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1373	1375	GCA	127;126;125	G,A;C;A	99,1;95;99	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	818	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2680	90.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1376	1378	ATC	125;125;125	A,G;T,G;C,A	100,1;95,1;96,1	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	818	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2680	90.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1388	1390	GTG	130;130;131	G,A,T;T,G;G	100,1,1;98,2;102	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	818	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2680	90.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1388	1390	GTG	130;130;131	G,A,T;T,G;G	100,1,1;98,2;102	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	818	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2680	90.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1892	1894	ACC	88;88;88	A,C;C;C	69,1;74;73	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	818	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2680	90.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1946	1948	GCG	96;94;93	G;C;G	73;66;63	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	818	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2680	90.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1946	1948	GCG	96;94;93	G;C;G	73;66;63	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	818	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2680	90.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2069	2071	GGC	88;88;88	G;G;C	70;72;71	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	818	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2680	90.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2078	2080	GGC	92;93;93	G,C;G;C	73,1;75;74	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	818	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2680	90.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2096	2098	CCG	96;95;95	C,G;C;G	77,1;77;75	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1178	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3507	100.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	654	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2225	87.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	751	751	C	89	C	75	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	74	porB1a	984	178	90.11	porB1a.l15.c4.ctg.1	1419	15.1	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1266	1268	AAT	10;10;10	A;A;T	8;8;8	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	74	porB1a	984	178	90.11	porB1a.l15.c4.ctg.1	1419	15.1	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1269	1271	AAT	9;9;9	A;A;T	7;7;7	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	74	porB1a	984	178	90.11	porB1a.l15.c4.ctg.1	1419	15.1	0	.	p	.	0	A222V	NONSYN	664	666	GCT	1281	1283	GTT	9;9;9	G;T;T	7;7;7	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	74	porB1a	984	178	90.11	porB1a.l15.c4.ctg.1	1419	15.1	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1293	1295	GCA	9;9;9	G;C;A	7;7;7	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	74	porB1a	984	178	90.11	porB1a.l15.c4.ctg.1	1419	15.1	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1316	1318	GTA	9;9;9	G;T;A	6;6;7	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	74	porB1a	984	178	90.11	porB1a.l15.c4.ctg.1	1419	15.1	0	.	p	.	0	N237fs	FSHIFT	709	709	A	1325	1325	A	9	A	7	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	680	porB1b	1047	1047	97.04	porB1b.l6.c30.ctg.1	1745	113.6	0	.	p	.	0	G38E	NONSYN	112	114	GGA	468	470	GAA	118;120;119	G;A;A	94;98;96	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	680	porB1b	1047	1047	97.04	porB1b.l6.c30.ctg.1	1745	113.6	0	.	p	.	0	S46G	NONSYN	136	138	AGC	492	494	GGC	120;120;121	G,A;G,A;C	98,1;97,1;95	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	680	porB1b	1047	1047	97.04	porB1b.l6.c30.ctg.1	1745	113.6	0	.	p	.	0	E48G	NONSYN	142	144	GAA	498	500	GGA	122;121;121	G;G,A;A	100;94,1;97	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	680	porB1b	1047	1047	97.04	porB1b.l6.c30.ctg.1	1745	113.6	0	.	p	.	0	T87A	NONSYN	259	261	ACT	615	617	GCT	131;132;131	G,A;C;T,C	109,1;108;99,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	680	porB1b	1047	1047	97.04	porB1b.l6.c30.ctg.1	1745	113.6	0	.	p	.	0	T89S	NONSYN	265	267	ACC	621	623	AGC	130;129;130	A;G,C;C	107;106,1;108	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	680	porB1b	1047	1047	97.04	porB1b.l6.c30.ctg.1	1745	113.6	0	.	p	.	0	.	MULTIPLE	358	359	AA	713	714	CG	141;140	C;G	114;110	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	680	porB1b	1047	1047	97.04	porB1b.l6.c30.ctg.1	1745	113.6	0	.	p	.	0	.	MULTIPLE	361	362	GA	716	718	CAG	140;141;142	C;A,G;G,A	114;113,1;114,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	680	porB1b	1047	1047	97.04	porB1b.l6.c30.ctg.1	1745	113.6	0	.	p	.	0	N122K	NONSYN	364	366	AAC	720	722	AAA	138;137;137	A;A;A,G,C	111;108;106,1,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	680	porB1b	1047	1047	97.04	porB1b.l6.c30.ctg.1	1745	113.6	0	.	p	.	0	K143E	NONSYN	427	429	AAA	783	785	GAA	139;139;140	G,A;A;A	111,2;107;109	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	680	porB1b	1047	1047	97.04	porB1b.l6.c30.ctg.1	1745	113.6	0	.	p	.	0	V151A	NONSYN	451	453	GTA	807	809	GCA	146;146;146	G,A;C;A	119,1;118;117	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	680	porB1b	1047	1047	97.04	porB1b.l6.c30.ctg.1	1745	113.6	0	.	p	.	0	A215T	NONSYN	643	645	GCT	999	1001	ACT	147;147;147	A;C;T,G,C	122;125;117,1,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	680	porB1b	1047	1047	97.04	porB1b.l6.c30.ctg.1	1745	113.6	0	.	p	.	0	I218M	NONSYN	652	654	ATA	1008	1010	ATG	149;149;149	A;T;G	125;122;124	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	680	porB1b	1047	1047	97.04	porB1b.l6.c30.ctg.1	1745	113.6	0	.	p	.	0	T256A	NONSYN	766	768	ACA	1122	1124	GCA	149;148;148	G;C;A,T	127;121;123,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	680	porB1b	1047	1047	97.04	porB1b.l6.c30.ctg.1	1745	113.6	0	.	p	.	0	W257T	NONSYN	769	771	TGG	1125	1127	ACG	149;150;151	A,T;C;G	126,1;125;129	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	680	porB1b	1047	1047	97.04	porB1b.l6.c30.ctg.1	1745	113.6	0	.	p	.	0	S258G	NONSYN	772	774	AGT	1128	1130	GGG	150;149;149	G;G;G,A	123;125;123,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	680	porB1b	1047	1047	97.04	porB1b.l6.c30.ctg.1	1745	113.6	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1131	1133	GTT	150;150;147	G;T;T	125;124;124	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	680	porB1b	1047	1047	97.04	porB1b.l6.c30.ctg.1	1745	113.6	0	.	p	.	0	L279V	NONSYN	835	837	TTA	1191	1193	GTA	149;149;152	G;T;A	124;124;124	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	680	porB1b	1047	1047	97.04	porB1b.l6.c30.ctg.1	1745	113.6	0	.	p	.	0	S292T	NONSYN	874	876	TCT	1230	1232	ACT	159;159;158	A;C;T	124;125;118	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	680	porB1b	1047	1047	97.04	porB1b.l6.c30.ctg.1	1745	113.6	0	.	p	.	0	H294D	NONSYN	880	882	CAT	1236	1238	GAT	158;158;159	G;A,T;T	126;118,1;125	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	680	porB1b	1047	1047	97.04	porB1b.l6.c30.ctg.1	1745	113.6	0	.	p	.	0	Y298H	NONSYN	892	894	TAC	1248	1250	CAC	158;159;160	C;A;C	125;120;126	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	680	porB1b	1047	1047	97.04	porB1b.l6.c30.ctg.1	1745	113.6	1	SNP	p	G120K	1	.	.	358	360	AAG	713	715	CGG	141;140;140	C;G;G,A	114;110;112,1	porB1b.WHO_L_01891c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	680	porB1b	1047	1047	97.04	porB1b.l6.c30.ctg.1	1745	113.6	1	SNP	p	A121D	1	.	.	361	363	GAC	716	719	CGC	140;142;140	C;G,A;C	114;114,1;113	porB1b.WHO_L_01891c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	680	porB1b	1047	1047	97.04	porB1b.l6.c30.ctg.1	1745	113.6	1	SNP	p	D121N	0	.	.	361	363	GAC	716	719	CGC	140;142;140	C;G,A;C	114;114,1;113	porB1b.WHO_L_01891c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	2274	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5280	129.1	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2229	2231	AAT	129;130;130	A;A;T,G	101;100;102,1	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	308	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1288	71.4	1	SNP	p	V57M	1	.	.	169	171	ATG	700	702	ATG	130;130;130	A;T,G;G	100;101,1;102	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
